Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California. Show more

1600 Sierra Point Parkway, Brisbane, CA, 94005, United States

https://www.nurixtx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.582B

52 Wk Range

$8.18 - $22.50

Previous Close

$15.78

Open

$15.77

Volume

759,218

Day Range

$15.29 - $16.49

Enterprise Value

1.42B

Cash

592.9M

Avg Qtr Burn

-67.83M

Insider Ownership

1.18%

Institutional Own.

Qtr Updated

11/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Bexobrutideg (NX-5948) Details Chronic lymphocytic leukemia (r/r CLL)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GS-6791 (NX-0479) Details Rheumatoid arthritis, Atopic dermatitis	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bexobrutideg (NX-5948) (BTK Degrader) Details Inflammation And Autoimmune Diseases	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bexobrutideg (NX-5948) Details Cancer, B-cell malignancies	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bexobrutideg (NX-5948) Details Waldenstrom macroglobulinemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zelebrudomide (NX-2127) Details Non-Hodgkin lymphoma, Blood cancer, Cancer, B-cell malignancies, Chronic lymphocytic leukemia, Mantle cell lymphoma, Diffuse large B cell lymphoma	Phase 1a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zelebrudomide (BTK Degrader) Details Relapsed Or Refractory B-Cell Malignancies	Phase 1a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NX-1607 +/- paclitaxel Details Solid tumor/s, Cancer	Phase 1a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NX-3911 (STAT6 Degrader) Details Autoimmune Diseases	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DeTIL-0255 Details Ovarian cancer, Cancer, Cervical cancer, Endometrial cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.